ViewRay (VRAY) Stock Price, News & Analysis

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ViewRay in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" VRAY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VRAY, but not buy additional shares or sell existing shares.
View VRAY analyst ratings or view top-rated stocks.

1 Wall Street analysts have issued 12-month price targets for ViewRay's shares. Their VRAY share price targets range from $1.00 to $2.00. On average, they anticipate the company's share price to reach $1.33 in the next twelve months.
View analysts price targets for VRAY or view top-rated stocks among Wall Street analysts.

ViewRay, Inc. (NASDAQ:VRAY) released its quarterly earnings data on Monday, February, 27th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. The firm earned $34.70 million during the quarter, compared to analyst estimates of $34.65 million. ViewRay had a negative trailing twelve-month return on equity of 120.48% and a negative net margin of 104.30%. ViewRay's revenue for the quarter was up 70.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.16) earnings per share.

5 employees have rated ViewRay Chief Executive Officer Scott Drake on Glassdoor.com. Scott Drake has an approval rating of 59% among the company's employees. This puts Scott Drake in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other ViewRay investors own include Alibaba Group (BABA), Amarin (AMRN), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Verastem (VSTM), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), AbbVie (ABBV), Accuray (ARAY) and Selecta Biosciences (SELB).

ViewRay (VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at a price of $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.